Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04043845
Title ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Dana-Farber Cancer Institute
Indications

marginal zone B-cell lymphoma

lymphoplasmacytic lymphoma

mantle cell lymphoma

chronic lymphocytic leukemia

Therapies

Ibrutinib + LY3214996

Age Groups: adult | senior
Covered Countries

Additional content available in CKB BOOST